^
Association details:
| Biomarker: | RORC overexpression |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | amezalpat (TPST-1120) (PPAR α antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
2130 / 4 - Lipid and immune-based biomarkers associated with clinical response to TPST-1120: A small molecule antagonist of peroxisome-proliferator activated receptor-alpha
Published date:
03/15/2023
Excerpt:
Patients with PR demonstrated significant elevations (p<0.05) in multiple genes including those associated with lipid transport (APOE), Th17 development (RORC) and down-regulation of CD155, a TIGIT ligand….TPST-1120 treated patients with PR demonstrated fatty acid oxidation perturbations and immune gene expression changes as potential biomarkers of clinical benefit.
